Expression of Vascular Endothelial Growth Factor Protein in Astrocytic Tumors.
- Author:
Se Hyuck PARK
1
;
In Bok CHANG
;
Chang Hyun KIM
;
Young Jun CHO
;
Byung Moon CHO
;
Dong Ik SHIN
;
Sae Moon OH
;
Duk Whan KIM
;
Eun Sook NAM
Author Information
1. Department of Neurosurgery, Hallym University College of Medicine, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Vascular endothelial growth factor;
Angiogenesis;
Astrocytoma
- MeSH:
Angiogenesis Inducing Agents;
Astrocytoma;
Biotin;
Capillary Permeability;
Endothelial Cells;
Glioblastoma;
Humans;
Male;
Necrosis;
Neoplasm Metastasis;
Streptavidin;
Vascular Endothelial Growth Factor A*
- From:Journal of Korean Neurosurgical Society
2001;30(6):683-687
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: Angiogenesis, the proliferation of capillary endothelial cells, is a vital component in the development, progression, and metastasis of many human tumors. Vascular endothelial growth factor(VEGF) is an endothelial cell-specific mitogen and induces angiogenesis and vascular permeability. The features of glioblastoma, distinct from low grade astrocytomas, are the presence of necroses and vascular endothelial proliferation. In this study, we investigated VEGF expression in the different grades of astrocytomas and determined whether VEGF expression correlates with development of glioblastoma and progression of astrocytomas. PATIENTS AND METHODS: Forty seven patients with astrocytic tumors(24 males and 23 females), aged 3 to 65 years, were evaluated. Immunohistochemical staining was carried out using labelled streptavidin biotin method and primary antibody was a antirabbit polyclonal Ab against N-terminus region of VEGF165(Oncogene research product, MA, USA). Immunoreactivity(IR) was classified into no IR(absent or a trace of stain), moderate IR and intense IR by level of staining amount and intensity. RESULTS: Six pilocytic astrocytomas showed 3 no IR and 3 moderate IR, 10 astrocytomas showed 2 no IR, 6 moderate IR and 2 intense IR, 12 anaplastic astrocytomas showed I no IR, 7 moderate IR and 4 intense IR and 19 glioblastomas showed 1 no IR, 11 moderate IR and 7 intense IR. Immunoreactivity was significantly different between low and high grade of tumors but there was no significant difference between anaplastic astrocytomas and glioblastomas. Gemistocytic tumor cells represented the predominent VEGF-immunoreactive cell types, as compared with compactly-arranged small tumor cells. In glioblastomas VEGF IR was observed in both perinecrotic and vital tumor areas. CONCLUSION: VEGF seems to be a important angiogenic factor in anaplastic astrocytomas and glioblastomas and VEGF expression may contribute to neovascularization of human astrocytomas.
